Table 2.
Presented Cases of Interstitial Pneumonia in Patients Who Developed ITP during the Course of Chronic Interstitial Pneumonia.
| Age/ Gender |
Platelet count (/µL) |
Complication | Autoantibodies | Previous therapy | Therapy for ITP | Outcome of interstitial pneumonia | Outcome of ITP | |
|---|---|---|---|---|---|---|---|---|
| Case 1 | 77/M | 18,000 | MPA, alveolar hemorrhage | MPO-ANCA, RF, ANA | none | PSL | slowly progressive | improvement |
| Case 2 | 77/M | 6,000 | alveolar hemorrhage | PR3-ANCA, RF, ANA | none | PSL, γ globulin | slowly progressive | improvement |
| Case 3 | 69/M | 15,000 | none | none | none | none | stable | natural improvement |
| Case 4 | 75/M | 2,000 | none | none | temporary steroid therapy for GBS | PSL | progressive | improvement |
| Case 5 | 71/M | 3,000 | none | none | none | PSL | slowly progressive | improvement |
| Case 6 | 81/M | 1,000 | alveolar hemorrhage | none | none | PSL | stable | improvement |
| Case 7 | 77/M | 50,000 | none | none | none | PSL | stable | stable |
M: male, ITP: immune thrombocytopenia, PSL: prednisolone, MPA: microscopic polyangiitis, RF: rheumatoid factor, MPO-ANCA: myeloperoxidase anti-neutrophil cytoplasmic antibody, ANA: antinuclear antibody, GBS: Guillain-Barré syndrome